A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
Authors:
- Tatsuro FukuharaTFTatsuro Fukuhara
- Kazuhiro ImaiKIKazuhiro Imai
- Taku NakagawaTNTaku Nakagawa
- Ryotaro IgusaRIRyotaro Igusa
- Hayato YokotaHYHayato Yokota
- Kana WatanabeKWKana Watanabe
- Aya SuzukiASAya Suzuki
- Mami MoritaMMMami Morita
- Ren OnoderaRORen Onodera
- Akira InoueAIAkira Inoue
- Masatomo MiuraMMMasatomo Miura
- Yoshihiro MinamiyaYMYoshihiro Minamiya
Open Access
- 10 September 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2501
Abstract
Osimertinib is a standard treatment for patients with EGFR-mutated non-small cell lung carcinoma (NSCLC). We evaluated the relationship between plasma osimertinib concentrations and treatment outcome in patients with NSCLC for this cohort study. The plasma levels of osimertinib and its metabolite AZ5104 were measured a week after the start of treatment (P1). The primary endpoint was to evaluate the correlation between plasma concentration and adverse events (AEs). The correlation with treatment efficacy was one of the secondary endpoints. In patients with CNS metastases, the concentration in the cerebrospinal fluid was also measured. Forty-one patients were enrolled. The frequency of AEs was highest for rash, followed by anorexia and thrombocytopenia. Thirty-eight cases provided measurements for P1. The median plasma concentration of osimertinib was 227 ng/mL, and that of AZ5104 was 16.5 ng/mL. The mean CNS penetration rate of two cases was 3.8%. The P1 in the group with anorexia was significantly higher than that in the group without anorexia (385.0 ng/mL vs. 231.5 ng/mL, p = 0.009). Divided into quartiles by P1 trough level, Q2 + Q3 (164–338 ng/mL) had longer PFS, while Q1 and Q4 had shorter PFS. An appropriate plasma level of osimertinib may avoid some adverse events and induce long PFS. Further large-scale trials are warranted.Keywords
Funding Information
- Miyagi Cancer Center
- Akita University
This publication has 26 references indexed in Scilit:
- Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor ReceptorDrug Metabolism and Disposition, 2016
- Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studiesCancer Chemotherapy and Pharmacology, 2016
- Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancerLung Cancer, 2016
- The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive MutationsScientific Reports, 2015
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerCancer Discovery, 2014
- A Limited Sampling Strategy for Estimation of the Area Under the Plasma Concentration–Time Curve of GefitinibTherapeutic Drug Monitoring, 2014
- Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokineticsCancer Chemotherapy and Pharmacology, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2012
- Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010